The objective of this systematic review and meta-analysis was to quantitatively assess outcomes after primary SFA stenting with nitinol stents in contemporary practice, to compare these rates with commonly used efficacy and safety goals, and to discuss the clinical and regulatory implications of these findings.
For example, the most commonly reported efficacy outcome was delivery delayed by 48 hours.
The most commonly reported efficacy measures were ACR-, European League Against Rheumatism (EULAR)- and DAS28-based response criteria.
Cohort-splitting studies most commonly compare efficacy in studies using the same endpoint for example, superiority to placebo as measured in head-to-head comparisons in different cohorts.
Studies for data comparison were selected if they had comparable study characteristics based upon consistent study design (multicenter, double-blind, randomized, placebo-controlled trials), length of treatment, and commonly reported efficacy [ADHD Rating Scale IV (ADHD-RS-IV) scores].
Commonly, the efficacy of these operational vector control interventions, if implemented properly and with coverage of almost the entire target population, protect the entire at-risk population [ 39, 44- 46] because the interventions reduce the density of indoor-biting Anopheles mosquitoes [ 47, 48] and hence diminish human vector contact and their vectorial capacity to transmit malaria parasites.
As a study of effectiveness, rather than the more commonly tested efficacy, this research extended the evidence-base for PDC, as well as for BRI Care Consultation (its parent intervention) by: 1) using a larger, more diverse sample than prior studies; and 2) delivering the program in a manner similar to the way it would be implemented if it were part of usual care.
The purpose of this analysis was to characterize the placebo response in antimuscarinic drug trials for OAB, based on changes in commonly-used efficacy endpoints.
The purpose of this analysis was to characterize the placebo response in antimuscarinic drug trials for OAB, based on changes in commonly-used efficacy endpoints of 1) number of micturitions per day, 2) number of incontinence episodes per day and 3) mean voided volume per micturition.
Although immunoglobulins and the antiviral agent ribavirin are commonly used, their efficacy remains uncertain.
